Justina Petrullo

It is possible, if you lay the groundwork, to provide patients with acute leukemias with aggressive and effective therapies, while still allowing them to maintain quality of life, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.

For many patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS), their disease will be chronic, giving them a long-term cancer experience, said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.

Alma Habib, MD, The Ohio State University Comprehensive Cancer Center, talks about the fact that disparities are able to be recognized in leukemia/lymphoma care, but the questions of how to address these disparities remain.

Older patients often face financial challenges on fixed incomes with different payer systems like Medicare, Sarah Wall, MD, The Ohio State University Comprehensive Cancer Center, says. Accessing treatment centers far away is difficult due to support system disruptions, leading to increased stress and financial strain.

Jennifer Vaughn, MD, discusses how value-based care in hematology should consider cost and financial toxicity, as well as valuable patient experience.

Patients with distant recurrent non–small cell lung cancer (NSCLC) had significantly better overall survival (OS) than patients who had de novo disease.

Jay Lee, MD, talks about financial toxicity in terms of the individual patient and in terms of the health system itself, especially in terms of non-small cell lung cancer (NSCLC) recurrence.

Andrew Ho, MD, talks about the importance of searching for what can be modified, such as closer transition to skilled nursing facilities, when working with patients who had pulmonary embolism (PE) and experienced readmission who had nonmodifiable factors and comorbidities.

Aparna Balasubramanian, MD, discusses the importance of measurements such as heart rate variability, but also that there’s no such thing as just 1 biomarker that will give all information for high-risk patients with chronic obstructive pulmonary disease (COPD).

Lower-sodium oxybate (LXB) and sodium oxybate (SXB) were proven equally effective for cataplexy and excessive daytime sleepiness (EDS), despite LXB having 92% less sodium.

Sarah Wall, MD, talks about how it’s important to consider patient age when treating older patients with cancer because it will impact so many of them and blood cancers act differently and can be more aggressive in older adults.

A close, updated review of data used to determine how to improve lung cancer screening rates and see who is most at risk of pulmonary complications is necessary to make progress in this area, notes Ajay Sheshadri, MD, MSCI.

Jeffrey Velotta, MD, FACS, attendee and presenter of CHEST Annual Meeting 2023, talks about the phenomenon of an increase in female, Asian, nonsmokers developing lung cancer, and what is being done to address this rise.

Aparna Balasubramanian, MD, assistant professor of medicine, Johns Hopkins School of Medicine, and attendee of the CHEST Annual Meeting 2023, talks about the necessity of challenging measurements like race-specific equations that can create harmful assumptions.

Sleep problems significantly increased between the first and second waves of the COVID-19 pandemic, which might be explained by detrimental sleep hygiene practices.

Sexual and gender minority (SGM) patients with chronic inflammatory skin diseases (CSIDs) may be disproportionately influenced by cost and noncost obstacles to health care.

Ajay Sheshadri, MD, discusses the advantages of attending CHEST 2023 in person and how these benefits can inspire positive change even after the conference ends.

Adam Kittai, MD, discusses how value and waste in treatment are imperative to consider in value-based care for blood-based cancers.

Drug maker payments to ophthalmologists were associated with the choice of higher-cost therapies for age-related macular degeneration (AMD) that could increase Medicare costs, but biosimilars could help.

Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone.

In part 3 of this 4-part series, Michael Thorpy, MD, talks about advances in sodium oxybate medication formulations and how different formulations can help patients depending on their needs.

A survey indicated that truncal acne may negatively impact adolescents’ and young adults’ quality of life and self-perception.

Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with adalimumab alone.

Women have a higher likelihood of having hormone receptor (HR+) non-small cell lung cancer (NSCLC) than men, and mutations of EGFR and KRAS were more common in HR+ NSCLC in a recent study.

Posttraumatic stress disorder (PTSD) symptoms and insomnia might be sex specific, and it is important to screen patients diagnosed with chronic insomnia for PTSD symptoms.

In part 2 of this 4-part series, Michael Thorpy, MD, discusses cases when a higher salt intake can be beneficial for some patients who have narcolepsy or daytime sleepiness.

Hidradenitis suppurativa (HS) may involve skin or nerve ending changes that could lead to peripheral neuropathy and changes in the transduction of specific stimuli.

No significant differences in resistance were observed against participants with acne vulgaris (AV) against 7 antibiotics.

Osimertinib administered in addition to chemotherapy showed more progression-free survival (PFS) benefit than just osimertinib in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC).

Automated ventilatory burden can effectively assess obstructive sleep apnea (OSA) severity, estimate cardiovascular (CVD) mortality, and may present a promising alternative to apnea-hypopnea index (AHI).